Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Feb;94(1):84-93.
doi: 10.1645/GE-1153.1.

Transcriptional inhibition of interleukin-12 promoter activity in Leishmania spp.-infected macrophages

Affiliations

Transcriptional inhibition of interleukin-12 promoter activity in Leishmania spp.-infected macrophages

Asha Jayakumar et al. J Parasitol. 2008 Feb.

Abstract

To establish and persist within a host, Leishmania spp. parasites delay the onset of cell-mediated immunity by suppressing interleukin-12 (IL-12) production from host macrophages. Although it is established that Leishmania spp.-infected macrophages have impaired IL-12 production, the mechanisms that account for this suppression remain to be completely elucidated. Using a luciferase reporter assay assessing IL-12 transcription, we report here that Leishmania major, Leishmania donovani, and Leishmania chagasi inhibit IL-12 transcription in response to interferon-gamma, lipopolysaccharide, and CD40 ligand and that Leishmania spp. lipophosphoglycan, phosphoglycans, and major surface protein are not necessary for inhibition. In addition, all the Leishmania spp. strains and life-cycle stages tested inhibited IL-12 promoter activity. Our data further reveal that autocrine-acting host factors play no role in the inhibitory response and that phagocytosis signaling is necessary for inhibition of IL-12.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Leishmania infection inhibits IL-12p40 transcription in murine macrophage cell line. RAW264.7 cells stably transfected with human IL-12p40-LUC construct were infected with L. major strain V1 and subsequently treated with 3 μg/ml CD40L ± 100 U/ml IFN-γ or 1 μg/ml LPS ± 100 U/ml IFN-γ. Samples were run in triplicate and mean relative luciferase units ± standard deviation is reported. * Infected values were significantly different from uninfected, stimulated controls (P < 0.05). † Uninfected, stimulated values were different from uninfected, untreated controls (P < 0.05). One representative of 3 independent experiments is presented.
Figure 2
Figure 2
Leishmania-induced IL-12p40 inhibition is independent of species and strain. RAW264.7 cells stably transfected with human IL-12p40-LUC construct were infected with different L. donovani (A) or L. major (B) substrains and treated with 100 U/ml IFN-γ plus 1 μg/ml LPS. Samples were run in triplicate and mean relative luciferase units ± standard deviation is reported. * Infected values were significantly different from uninfected, stimulated controls (P < 0.05). † Uninfected, stimulated values were different from uninfected, untreated controls (P < 0.05). In each case 1 representative of 2 independent experiments is shown.
Figure 3
Figure 3
Inhibition of IL-12p40Luc by different Leishmania spp. life-cycle stages. RAW264.7 cells stably transfected with human IL-12p40-LUC construct were infected with L. major strain V1 life-cycle stages for 16 hr followed by 8 hr of LPS (1 μg/ml) stimulation. Life-cycle stages (met = metacyclic; log = log-phase promastigotes; am = amastigotes). Samples were run in triplicate and mean relative luciferase units ± standard deviation is reported. * Infected values were significantly different from uninfected, stimulated controls (P < 0.05). † Uninfected, stimulated values were different from uninfected, untreated controls (P < 0.05). One representative of 2 independent experiments is shown.
Figure 4
Figure 4
Inhibition of IL-12p40Luc by Leishmania spp. products. RAW264p7 cells stably transfected with human IL-12p40-LUC construct were infected with L. major strain V1 or treated with parasite products for 16 hr followed by 8 hr of LPS (1 μg/ml) stimulation. (A) Parasite products (Live = live metacyclic infection; Lysate = freeze–thaw lysates; HK = heat-killed metacyclics). (B) Secreted products (V1 = live metacyclic infection; Neat, Dil, Conc = cultured parasite supernantants either diluted or concentrated). Samples were run in triplicate and mean relative luciferase units ± standard deviation is reported. * Infected values were significantly different from uninfected, stimulated controls (P < 0.05). † Untreated, stimulated values were different from untreated, media controls (P < 0.05). In each case 1 of 3 independent experiments is shown.
Figure 5
Figure 5
Inhibition of IL-12p40Luc by Leishmania is not dependent on LPG, PG, or GP63. RAW264.7 cells stably transfected with human IL-12p40-LUC construct were infected with Leishmania for 16 hr followed by 8 hr of LPS (1 μg/ml) stimulation. (A) Leishmania donovani wild-type, LPG-deficient, and PG-deficient mutants. (B) Leishmania mexicana wild-type and GP63-deficient mutant. Samples were run in triplicate and mean relative luciferase units ± standard deviation is reported. * Infected values were significantly different from uninfected, stimulated controls (P < 0.05). † Uninfected, stimulated values were different from uninfected, untreated controls (P < 0.05). One representative of 2 independent experiments is shown.
Figure 6
Figure 6
Inhibition of IL-12p40Luc by Leishmania does not involve autocrine MP factors; 1 × 106 RAW264.7 cells stably transfected with human IL-12p40-LUC construct were plated in lower wells and 1 × 106 were plated in upper wells of a transwell system. Cells were infected with L. major at a 5:1 ratio for 2 hr followed by IFN-γ (100 U/ml) stimulation for 16 hr and LPS (1 μg/ml) stimulation for 8 hr. Luciferase values were detected from cells in lower chambers. Samples were run in triplicate and mean relative luciferase units ± standard deviation is reported. * Infected values were significantly different from uninfected, stimulated controls (P < 0.05). † Uninfected, stimulated values were different from uninfected, untreated controls (P < 0.05). One representative of 3 independent experiments is shown.
Figure 7
Figure 7
Inhibition of IL-12p40Luc by Leishmania requires phagocytosis. RAW264.7 cells stably transfected with human IL-12p40-LUC construct were untreated (A, C) or pretreated with 1 μM cytochalasin D (B, D), then infected with L. major strain V1 and subsequently treated with 1 μg/ml LPS ± 100 U/ml IFN-γ. Samples were run in triplicate, treated with IFN-γ + LPS, and assessed for luciferase production (A, B) or endogenous levels of IL-12p40 by quantitative RT-PCR (C, D). Mean percentage expression ± standard deviation of is reported. * Infected values were significantly different from uninfected, stimulated controls (P < 0.05). One representative of 2 independent experiments is presented.

Similar articles

Cited by

References

    1. Aste-Amezaga M, Ma X, Sartori A, Trinchieri G. Molecular mechanisms of the induction of IL-12 and its inhibition by IL-10. Journal of Immunology. 1998;164:5936–5944. - PubMed
    1. Belkaid Y, Butcher B, Sacks DL. Analysis of cytokine production by inflammatory mouse macrophages at the single-cell level: Selective impairment of IL-12 induction in Leishmania-infected cells. European Journal of Immunology. 1998;28:1389–1400. - PubMed
    1. Belkaid Y, Mendez S, Lira R, Kadambi N, Milon G, Sacks D. A natural model of Leishmania major infection reveals a prolonged “silent” phase of parasite amplification in the skin before the onset of lesion formation and immunity. Journal of Immunology. 2000;165:969–977. - PubMed
    1. Berger S, Chandra R, Ballo H, Hildenbrand R, Stutte HJ. Immune complexes are potent inhibitors of interleukin-12 secretion by human monocytes. European Journal of Immunology. 1997;27:2994–3000. - PubMed
    1. Blanchette J, Racette N, Faure R, Siminovitch KA, Olivier M. Leishmania-induced increases in activation of macrophage SHP-1 tyrosine phosphatase are associated with impaired IFN-gamma-triggered JAK2 activation. European Journal of Immunology. 1999;29:3737–3744. - PubMed

Publication types

MeSH terms